EDAP TMS S.A. to Participate in International Urology Conferences LYON, France -- EDAP TMS S.A. (Nasdaq: EDAP), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer, today announces it is actively participating in the Societe Internationale d'Urologie (SIU)

Adds to Executive Team for Ongoing Growth, Expansion

Clinical Updates Presented From French Luminary Centers, Marketing Programs Attracting Inquiries

Proven Senior Professionals Added in Growth Markets

EDAP Sonolith Vision Achieves Top Outcomes in Stone Free Rates An October 2006 publication in the Journal of Endourology compared lithotripsy outcomes for the EDAP Sonolith Vision against the Dornier Compact Delta and the Dornier HM-3, widely considered the Gold Standard in lithotripsy outcomes.

Canadian Medical Company Secures Second Ablatherm in North America

Marc Oczachowski to Assume CEO Role Hugues de Bantel to Join Board with Focus on French and US Programs

French Public Clinics Expand Ablatherm HIFU Commitment

EDAP Leveraging Positions in Europe for HIFU; Finalizing US Market Strategy

EDAP TMS S.A. Announces Exclusive Distribution of New Muscle Trainer Device in Japan Lyon, France, January 30, 2007 - EDAP TMS S.A. (Nasdaq: EDAP ), the global leader in High Intensity Focused Ultrasound (HIFU) treatment of prostate cancer and the international leader in the development,